Personal Independent Payment Assessments Are an Excuse to Strip Assistance Away From People With Disabilities
source: pixabay.com

Personal Independent Payment Assessments Are an Excuse to Strip Assistance Away From People With Disabilities

According to a story from The Independent, Britain's disability welfare program is coming under fire for its Personal Independent Payment (PIP) assessments. Statistical measures suggest that these assessments are taking…

Continue Reading Personal Independent Payment Assessments Are an Excuse to Strip Assistance Away From People With Disabilities
Way More Babies are Affected by Fetal Alcohol Spectrum Disorder Than We Originally Thought
Free-Photos / Pixabay

Way More Babies are Affected by Fetal Alcohol Spectrum Disorder Than We Originally Thought

While it seems to be common knowledge that drinking while pregnant is unwise, many children are harmed by the effects of fetal alcohol spectrum disorder, reported CNN. Older studies suggest…

Continue Reading Way More Babies are Affected by Fetal Alcohol Spectrum Disorder Than We Originally Thought
New Digital Therapies Developed For Schizophrenia and Multiple Sclerosis Patients
Source: Pixabay

New Digital Therapies Developed For Schizophrenia and Multiple Sclerosis Patients

Novartis and Pear Therapeutics have joined forces to develop digital therapeutic software applications to treat patients with schizophrenia and multiple sclerosis, reports World Pharma News. Novartis is known for the…

Continue Reading New Digital Therapies Developed For Schizophrenia and Multiple Sclerosis Patients
The FDA is Beginning to Accept New Endpoints and “Real World” Data in Clinical Trials
vitalworks / Pixabay

The FDA is Beginning to Accept New Endpoints and “Real World” Data in Clinical Trials

According to a story from Charcot-Marie-Tooth Disease News, the U.S. Food and Drug Administration (FDA), under the leadership of commissioner Scott Gottlieb, has begun to change clinical trials by accepting…

Continue Reading The FDA is Beginning to Accept New Endpoints and “Real World” Data in Clinical Trials